# Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

> **NCT00278889** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 215 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** AZD2171
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00278889
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-11
- **Final completion:** 2009-10
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2012-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278889, "Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00278889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*